Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[225Ac]Ac-mcp-TDI-Y-010
- Development stage
- Preclinical
- Lead developer
- Tri-Institutional Therapeutics Discovery Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[225Ac]Ac-mcp-TDI-Y-010 is a targeted alpha-particle radioimmunotherapy (RIT) agent designed for the treatment of neuroendocrine cancers. It consists of the monoclonal antibody TDI-Y-010, which specifically targets Delta-like ligand 3 (DLL3), conjugated to the alpha-emitting radionuclide Actinium-225 (225Ac) using a MACROPA-derived chelator (mcp). DLL3 is an atypical Notch ligand that is highly overexpressed on the surface of various neuroendocrine tumors, such as small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC), while having minimal expression in normal tissues. Upon binding to DLL3-expressing cells, the agent delivers high-energy alpha particles that induce lethal double-stranded DNA breaks, leading to tumor cell death. Preclinical evaluations have shown significant antitumor activity and manageable toxicity, positioning it as a promising candidate for clinical development in DLL3-positive malignancies.
- Other names
- 225Ac-mcp-TDI-Y-010Actinium-225-mcp-TDI-Y-010Actinium225-mcp-TDI-Y-010Actinium 225-mcp-TDI-Y-010
02
Targets
DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on [225Ac]Ac-mcp-TDI-Y-010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [225Ac]Ac-mcp-TDI-Y-010.